Drugs / JNJ-74699157
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04006301 | Jul 2019 → Jul 2020 | colorectal cancer, non-small cell lung carcinoma | Janssen Research & Development, LLC | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ-74699157 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04006301 ↗ |
| Action | Inhibit | “an oral, selective, covalent inhibitor of the KRAS G12C isoform” PMID 35325211 ↗ Jul 2022 |
| Route | Oral | “Participants will receive JNJ-74699157 orally.” NCT04006301 ↗ |
| Target | KRAS | “inhibitor of the KRAS G12C isoform” PMID 35325211 ↗ Jul 2022 |